主页 > 医药科学 >
【medical-news】月经血可治疗周围血管病变
ScienceDaily (Aug. 19, 2008) — Cells obtained from menstrual blood, termed 'endometrial regenerative cells' (ERCs) are capable of restoring blood flow in an animal model of advanced peripheral artery disease. A new study demonstrates that when circulation-blocked mice were treated with ERC injections, circulation and functionality were restored.
Critical limb ischemia, an advanced form of peripheral artery disease, causes approximately 150,000 amputations per year in the US. Currently there are no medical or surgical interventions that are effective in the advanced stages of the disease. ERCs are cells taken from menstrual blood that are capable of forming into at least 9 different tissue types, including heart, liver and lung.*
Dr. Michael Murphy, a vascular surgeon from Indiana University and lead author of this study has already performed clinical trials with adult stem cells for patients with peripheral artery disease. He stated, "The advantage of ERCs is that they can be used in an 'off the shelf' manner, meaning they can be delivered to the point of care, do not require matching, and are easily injectable without the need for complex equipment."
The experiments were performed as a collaboration between University of Western Ontario, Scripps Research Institute, Indiana University, and several other academic centers. The ERC cell population is currently being developed by the US publicly traded company Medistem Inc, who supported these studies.
"We are proud of assembling such a strong, clinically experienced team to contribute to these studies" said Dr. Thomas Ichim, CEO of Medistem. "Dr. Ewa Carrier and Suman Kambhampati are hematologists who use stem cells on a regular basis, Dr. Angle is a vascular surgeon, who like Dr. Murphy sees CLI on a daily basis, and Dr. Amit Patel has performed numerous cardiac stem cell clinical trials. With such a team that understands not only the science, but also the practical implementation, we feel we are well positioned to translate this discovery into a practical therapy in the near future".
* This discovery won the 'Medicine Research Award of the Year' award for BioMed Central's Research Awards in 2007.
http://www.sciencedaily.com/releases/2008/08/080818220609.htm 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Limbs Saved By Menstrual Blood Stem Cells
月经血干细胞可挽救肢体
ScienceDaily (Aug. 19, 2008) — Cells obtained from menstrual blood, termed 'endometrial regenerative cells' (ERCs) are capable of restoring blood flow in an animal model of advanced peripheral artery disease. A new study demonstrates that when circulation-blocked mice were treated with ERC injections, circulation and functionality were restored.
每日科学（2008年8月19日）－在进展期外周血管病变的动物模型中，采集自月经血的细胞－也被称为“子宫内膜源细胞”(ERCs)－能够重建血流。一项新的研究显示，当患有循环闭塞的实验鼠接受了ERC注射后，循环和功能得到了重建。
Critical limb ischemia, an advanced form of peripheral artery disease, causes approximately 150,000 amputations per year in the US. Currently there are no medical or surgical interventions that are effective in the advanced stages of the disease. ERCs are cells taken from menstrual blood that are capable of forming into at least 9 different tissue types, including heart, liver and lung.*
在美国，每年由外周血管进展引起的急性肢体缺血导致了大约150,000患者截肢。目前，在该病进展期，尚缺乏药物或手术干预来有效治疗方式。ERCs是采集自月经血的的细胞，它能够分化成至少9种不同类型的细胞，包括心脏、肝脏和肺脏。
Dr. Michael Murphy, a vascular surgeon from Indiana University and lead author of this study has already performed clinical trials with adult stem cells for patients with peripheral artery disease. He stated, "The advantage of ERCs is that they can be used in an 'off the shelf' manner, meaning they can be delivered to the point of care, do not require matching, and are easily injectable without the need for complex equipment."
Michael Murphy博士是印第安纳州大学血管外科医生，也是这项研究的领导者，他先前进行了成人干细胞治疗外周血管疾病的临床实验。他表示，，ERCs的优势在于它们能够在“无载体的情况下使用”，这意味着它们能够到达治疗点，无需匹配，能方便地注射而无需特别复杂的装备。
The experiments were performed as a collaboration between University of Western Ontario, Scripps Research Institute, Indiana University, and several other academic centers. The ERC cell population is currently being developed by the US publicly traded company Medistem Inc, who supported these studies.
该实验由Western Ontario大学、 Scripps Research Institute和 Indiana大学及其他数个学术中心共同合作研究。目前ERC细胞由支持这些研究的大众商业公司Medistem Inc提供。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-14 17:14
医学,生命科学网